Free Trial
NASDAQ:ARTL

Artelo Biosciences Q1 2025 Earnings Report

Artelo Biosciences logo
$1.00 -0.04 (-3.40%)
As of 03:50 PM Eastern

Artelo Biosciences EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.59
One Year Ago EPS
N/A

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Artelo Biosciences Earnings Headlines

Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday
New Way of Trading Has Gone Viral
Imagine foreseeing a 30% stock jump — to the day — weeks before it happens. Introducing a new way to predict the biggest stock jumps this spring, to the day, with 83% backtested accuracy. In 2024 alone, it would've pointed to gains of 250% in 38 days on (TTWO)… 101% in 10 days on (WSM)… 353% in 48 days on (AON) and more in studies.
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL), a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

View Artelo Biosciences Profile

More Earnings Resources from MarketBeat